Summary
Twenty evaluable patients with advanced measurable colorectal cancer received 3-week courses of a combination of IV dacarbazine 300 mg/m2/day from day 1 to day 5 and IV mitomycin 2 mg/m2/day from day 1 to day 5. Fourteen of these patients had had no prior chemotherapy and received two or more courses of this two-drug regimen. None of the patients achieved complete or partial response. Severe to life-threatening myelosuppression, was encountered in patients with prior radiotherapy and or prior chemotherapy, and/or in patients with a Karnofsky score ≤70. Hematologic toxicity was mild in the other patients. Nonhematologic toxic effects were generally mild to moderate and consisted essentially in nausea and vomiting. It is concluded that in our hands the regimen selected for this trial has no significant antitumor activity in advanced colorectal cancer.
References
Beretta G, Labianca R, Luporini G (1981) Evaluation of the combination dacarbazine (DIC) + mitomycin C (MMC) in advanced colorectal carcinoma. Proc AACR/ASCO 22:449
Conroy JF, Roda PI, Brodsky I, Kahn SB, Bulova SI, Pequignot E (1981) Efficacy of dacarbazine imidazole carboxamide and mitomycin C combination therapy in patients with adenocarcinoma of the colon refractory to 5-fluorouracil therapy. Recent Results Cancer Res 79:93
Moertel CG (1975) Clinical management of advanced gastrointestinal cancer. Cancer 36:675
Slavik M (1976) Clinical studies with DTIC (NSC-45388) in various malignancies. Cancer Treat Rep 60:213
Staquet MJ, Rozencweig M, Von Hoff DD, Muggia FM (1979) The delta and epsilon errors in the assessment of cancer clinical trials. Cancer Treat Rep 63:1917
Author information
Authors and Affiliations
Consortia
Rights and permissions
About this article
Cite this article
Bleiberg, H., Clavel, M., Nicaise, C. et al. Combination of dacarbazine and mitomycin in advanced colorectal cancer. Cancer Chemother. Pharmacol. 10, 68–69 (1982). https://doi.org/10.1007/BF00257242
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00257242